leisure time -WSS

leisure time

author：focus 2025-10-01 02:15:20 - browse：9798

Adam's take main illustration — Molly Ferguson/STAT

Happy Groundhog Day eve. Some takes and thoughts on Bluebird Bio’s quest for gene therapy profits, a reality check on Vertex’s highly touted pain drug, and more ADC investor FOMO.

Bluebird and the case for gene therapy profits

Genetic treatments that are potential cures for inherited diseases are a huge medical advance, but can these transformational (and expensive) products become a profitable business? I’m not sure anyone knows yet for sure, but pay attention to Bluebird Bio over the next year for some clues.

Bluebird is unique among the biotech and pharma companies selling gene therapies (or CRISPR-based medicines) today because it has no other marketed products. With the recent approval of Lyfgenia for sickle cell disease (cost: $3.1 million), Bluebird sells three gene therapies. The other products are Zynteglo for beta thalassemia ($2.8 million) and Skysona for cerebral adrenoleukodystrophy ($3 million). It’s a pure-play commercial gene therapy business. It’s not even trying to develop additional gene therapies currently. R&D expenses are tied to gathering long-term data on its existing products.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Susan Tousi leaves Illumina to head cancer liquid biopsy startup

hotspot

WSS

Feng Zhang, Grail founder join forces on new gene editing startup

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

3 medical device trends to watch in 2024

JPM: CVS says Medicare Advantage patients are impacting profits

How medical schools plan to diversify without affirmative action

FDA approves updated Covid vaccines

focus

leisure time

Bluebird and the case for gene therapy profits

focus

Virginia high school admissions case could be legal follow

Long Covid needs a new name — and a new frame

Medical leaders decry Supreme Court decision on affirmative action

How housing is health care on Long Island

Trump demands the U.S. pay no more for drugs than other countries … again

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

DIEP, the 'gold standard' of breast reconstruction, is under threat

White House finalizes ITC's import ban of latest Apple Watches

Sports medicine is finally prioritizing gender equality

Diverse clinical trials: Why aren’t we there yet?

knowledge

Will the IRA bring competition to the biologics market?

Hospitals consider fixing cancer drug shortages on their own

Videos point to link between seizures and unexplained toddler deaths

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

entertainment

hotspot

hotspot

focus